Teclistamab is safe and effective in relapse refractory multiple myeloma patients with end stage renal disease: a case series

all relapse cohorts, which correlated with enhanced T-cell activation and degranulation (Pearson´s r=0.7).Conclusions: SAR442257 has increased binding capacity for RRMM due to CD38 and CD28 targets and demonstrated activity on RRMM cells as reasonable alternative for future RRMM therapy approach.